@Article{,
AUTHOR = {Gilles Karsenty, Abdulaziz Baazeem, Ehab Elzayat, Jacques Corcos},
TITLE = {Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {13},
YEAR = {2006},
NUMBER = {2},
PAGES = {3027--3033},
URL = {http://www.techscience.com/CJU/v13n2/62494},
ISSN = {1488-5581},
ABSTRACT = {The first application of botulinum toxin type A (BTA)
in urology was its injection into the urinary sphincter
to treat neurogenic detrusor-sphincter dyssynergia
(DSD) in quadriplegic men. Since that first report in
the eighties, the results of focal BTA injections into
the sphincter, the bladder wall and lately into the
prostate, have raised the interest of the urology
community in this promising new therapeutic
modality. An evidence-based review is presented of
current indications, techniques and outcome of BTA
injections into the urethral sphincter.},
DOI = {}
}